Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Psychopharm Cmte. Crafts Statement To Avoid Public Misunderstanding

Executive Summary

FDA's Psychopharmacologic Drugs Advisory Committee crafted a statement on the need for long-term efficacy data for psychiatric drugs in order to avoid public misperception of the outcome of its Oct. 25 meeting
Advertisement

Related Content

Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
Antidepressant Long-Term Efficacy Pre-Approval Will Be Voted On By Cmte.
Antidepressant Long-Term Efficacy Pre-Approval Will Be Voted On By Cmte.
FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals
FDA Will Strengthen Antidepressant Warnings; “Black Box” Not Certain

Topics

Advertisement
UsernamePublicRestriction

Register

PS046497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel